Literature DB >> 2386402

Effect of indomethacin on binding of bilirubin to albumin.

B C Lam1, H N Wong, C Y Yeung.   

Abstract

The effect of indomethacin on the binding of bilirubin to protein was studied in vitro by the horseradish peroxidase oxidation method. Plasma indomethacin concentrations ranging from 1500 micrograms/l to 4500 micrograms/l, which were much higher than the therapeutic concentrations achieved in vivo, were used for the studies. The bilirubin-protein titration curves obtained indicate that indomethacin, although protein bound, does not affect the binding of bilirubin to protein. Our study confirms that it is safe to use conventional doses of indomethacin in jaundiced preterm infants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386402      PMCID: PMC1590185          DOI: 10.1136/adc.65.7_spec_no.690

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  12 in total

1.  Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro.

Authors:  R W Mason; E G McQueen
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

2.  Determination of unbound bilirubin in the serum of newborns.

Authors:  J Jacobsen; R P Wennberg
Journal:  Clin Chem       Date:  1974-07       Impact factor: 8.327

3.  Pharmacological closure of ductus arteriosus in preterm infants using indomethacin.

Authors:  H I Obeyesekere; S Pankhurst; V Y Yu
Journal:  Arch Dis Child       Date:  1980-04       Impact factor: 3.791

4.  Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus.

Authors:  P Vert; G Bianchetti; F Marchal; P Monin; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

5.  Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure.

Authors:  C A Friedman; B R Parks; J E Rawson; G A Serwer; P A Anderson
Journal:  Dev Pharmacol Ther       Date:  1982

6.  Disposition of indomethacin in preterm infants.

Authors:  R Bhat; D Vidyasagar; M Vadapalli; C Whalley; E Fisher; A Hastreiter; M Evans
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

7.  Indomethacin and bilirubin-albumin binding.

Authors:  S Shankaran; A Pantoja; R L Poland
Journal:  Dev Pharmacol Ther       Date:  1982

8.  Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection.

Authors:  A Leonhardt; V Isken; P G Kühl; H W Seyberth
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

9.  Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels.

Authors:  R M Nestrud; D E Hill; R W Arrington; A G Beard; W T Dungan; P Y Lau; J B Norton; R I Readinger
Journal:  Dev Pharmacol Ther       Date:  1980

10.  Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus--a double-blind controlled study.

Authors:  T F Yeh; J A Luken; A Thalji; D Raval; I Carr; R S Pildes
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

View more
  2 in total

1.  Ibuprofen for closure of patent ductus arteriosus: is it really safe in hyperbilirubinaemic infants?

Authors:  Thor Willy Ruud Hansen
Journal:  Eur J Pediatr       Date:  2003-02-27       Impact factor: 3.183

Review 2.  Patent ductus arteriosus in the newborn.

Authors:  N Archer
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.